Table 3.
Baseline table
| Study | Treatment form | Relevant participants | Gender (male) | Mean age (SD or range) | Uni-/bilateral | Research duration (years) | Dosage (mg/kg) | Therapy period (days) | Treatment after onset (days) | Follow-up (months) | Salvage or primary treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cekin et al. | Hyperbaric oxygen therapy + oral prednisolone | 36 | 24 | 46.8 ± 14.5 | Uni (34×)/Bi (2×) | 12 | 1 | 21 | ● | ● | Primary |
| Oral prednisolone | 21 | 8 | 44.5 ± 16.3 | Uni | 12 | 1 | 21 | ● | ● | Primary | |
| Topuz et al. | Oral prednisolone + HBO | 30 | 14 | 42.1 ± 13.4 | Uni | 4 | 5 + 2.5 ATA | 15 | < 14 | 1 | Primary |
| Oral prednisolone | 21 | 12 | 40.4 ± 11.2 | Uni | 4 | 5 | 14 | < 14 | 1 | Primary | |
| Fujimura et al | Dexamethasone oral + HBO | 63 | ● | 53.0 ± 2.1 | Uni | 3 | 10 − 5 | 14 | < 30 | 1 | Primary |
| Dexamethasone oral | 67 | ● | 52.2 ± 1.7 | Uni | 11 | 10 − 5 | 14 | < 30 | 1 | Primary | |
| Pezzoli et al. | Dexamethasone IV + HBO | 23 | 16 | 47.3 ± 13.7 | ● | 2 | 25 + 2.5 ATA | 7 + 15 | < 30 | 0.3 | Salvage |
| Dexamethasone IV | 21 | 11 | 54.5 ± 13.1 | ● | 2 | 25 | 7 | < 30 | 0.3 | Salvage | |
| Alimoglu et al.a | Oral prednisolone + HBO | 61 | ● | ● | Uni | 6 | 1 mg/kg | 21 | < 30 | 2 | Primary |
| Oral prednisolone | 58 | ● | ● | Uni | 6 | 1 mg/kg | 21 | < 30 | 2 | Primary | |
| Yang chao et al.a | Dexamethasone ITS + HBO | 19 | 6 | 44.68 ± 16.04 | Uni | ● | 5 mg/ml + 2.5 ATA | 14 | < 14 | 3 | Salvage |
| Dexamethasone ITS | 35 | 19 | 49.71 ± 15.43 | Uni | ● | 5 mg/ml | 14 | < 14 | 3 | Salvage | |
| Khater et al. | Intratympanic steroid injection + HBO | 11 | 5 | 45.9 ± 6.9 | Uni | 1 | 40 mg/ml + 2 ATA | 7 + 20 | ● | 1 | Primary |
| Intratympanic steroid injection | 11 | 7 | 45.8 ± 7.14 | Uni | 1 | 40 mg/ml | 7 | ● | 1 | Primary | |
| Liu et al.a | Oral prednisolone + HBO | 112 | 20 | 42.4 ± 14.3 | Uni | 10 | 20 + 2.5 ATA | 8 + 20 | < 14 | ● | Primary |
| Oral prednisolone | 277 | 88 | 44.0 ± 17.0 | Uni | 10 | 20 | 8 | < 14 | ● | Primary | |
| Tasdoven et al.a | Oral prednisolone + HBO | 26 | ◘ | 50 ± 13 | Uni | 2 | 1 (mg/kg) | 5 | ● | 3 | Primary |
| Oral prednisolone | 63 | ◘ | 50 ± 13 | Uni | 2 | 1 (mg/kg) | 5 | ● | 3 | Primary | |
| Ajduk et al. | Intravenous methylprednisolone + HBO | 43 | 21 | 53.2 ± 19.4 | ● | 6 | 240/ 80 | 8 | < 20 | 1 | Salvage |
| Intravenous methylprednisolone | 50 | 25 | 55.5 ± 22.2 | ● | 6 | 240/ 80 | 8 | < 20 | 1 | Salvage | |
| Callioglu et al. | Oral prednisolone + HBO | 21 | 12 | 43.1 ± 14.8 | Uni | 2 | 60/20 + 2.5 ATA | 10/3 + 16 | < 30 | ◘ | Primary |
| Oral prednisolone | 23 | 18 | 49.4 ± 12.6 | Uni | 2 | 60/20 | 10/3 | < 30 | ◘ | Primary | |
| Edizer et al. | Oral prednisolone + HBO | 21 | 12 | 45.9 ± 15.4 | Uni | 5 | 60 + 2.5 ATA | 7 + 20 | < 30 | 6 | Primary |
| Oral prednisolone | 23 | 18 | 45.9 ± 15.4 | Uni | 5 | 60 + 2.5 ATA | 7 | < 30 | 6 | Primary | |
| Satar et al. | Oral dexamethasone + HBO | 37 | 25 | 45.2 ± 15.4 | Uni (34×)/bi (3×) | 7 | 4 + 2.5 ATA | 15 | < 5 | ● | Primary |
| Oral dexamethasone | 17 | 11 | 46 ± 17.9 | Uni | 7 | 4 | 15 | < 15 | ● | Primary | |
| Aslan et al. | Oral prednisolone + HBO | 25 | 17 | 48 ± 18.4 | Uni | 4 | 1 mg/kg + 2.5 ATA | 14 + 13 | < 14 | 2 | Primary |
| Oral prednisolone | 25 | 15 | 46.6 ± 17 | Uni | 4 | 1 mg/kg | 14 | < 14 | 2 | Primary | |
| Narozny et al. | Oral prednisolone + HBO | 52 | 31 | 39 ± 16 | Uni | 4 | 60 + 2.5 ATA | 14 + 16 | ◘ | ● | Primary |
| Oral prednisolone | 81 | 32 | 42 ± 19 | Uni | 17 | 30 + 2.5 ATA | 14 | ◘ | ● | Primary | |
| Chi et al. | Oral prednisolone + HBO | 30 | 27 | 31.1 ± 12.6 | Uni | 9 | 20 + 2.5 ATA | 14 + 5 | < 10 | 6 | Primary |
| Oral prednisolone | 30 | 26 | 29.5 ± 14.7 | Uni | 9 | 20 | 14 | < 10 | 6 | Primary |
● not reported, ■ not conducted, ◘ not extractable, Uni unilateral, Bi bilateral, Total dosage total medication given
aMore than two groups were screened